Drug Development

New Drug Disrupts "Zipper" Crucial to HIV-1 Infectivity

Published in Gene Therapy Weekly, May 1st, 1995

A novel synthetic peptide is the first of what may be a new class of anti-HIV agents that prevent the virus from entering cells.

The finding may lead to new drugs and gene therapies for AIDS.

The peptide, called DP-178, is an analog of a parent peptide created in 1992 by Duke University researcher Carl Wild and colleagues. Wild et al. created the original peptide, DP-107, in order to study the function of the HIV-1 gp41 transmembrane glycoprotein. DP-107 corresponds to amino-acid residues 558 to 595 of gp41.

To their surprise, the peptide had potent anti-HIV activity.

Since their initial discovery, Wild et...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-05-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry